MF59-adjuvanted vaccine: A safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

Expert Opinion on Biological Therapy

Volumn 10, Issue 4, 2010, Pages 639-651

  Durando, Paolo ^a   Icardi, Giancarlo ^a   Ansaldi, Filippo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cross reactivity; Immunogenicity; Influenza vaccines; MF59 adjuvant; Safety

Indexed keywords

INFLUENZA VACCINE; INTANZA; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CROSS REACTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; PNEUMONIA; PROPHYLAXIS; REVIEW; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SEASONS; SQUALENE;

ORTHOMYXOVIRIDAE;

EID: 77949430350     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003724662     Document Type: Review

References (105)

1. Nguyen-van-Tam JS, Nicholson KG. Influenza deaths in Leicestershire during the1989-90 epidemic: implications for prevention. Epidemiol Infect 1992;108:537-545
2. Sprenger MJ, Mulder PG, Beyer WE, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993;22:334-340
3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186
4. Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 2000;30:931-933
5. World Health Organization (WHO). Influenza vaccines. Wkly Epidemiol Rec 2005;80:279-287
6. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;6:1-40
7. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009;58:RR-8
8. Neuzil KM, Wright PF, Mitchel EF, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000;137:856-64
9. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31
10. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9
11. World Health Organization (WHO). Fact sheet 2003;21. Available from: http://www.who.int/mediacentre/factsheets/fs211/en
12. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-5096
13. Gasparini R, Lucioni C, Lai P, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002;20:B50-4
14. Italian Ministry of Welfare, Health and Social policies. Circular 23 July 2009 Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2009-2010. Available from: http://www.normativasanitaria.it/normsan-pdf/0000/ 29731-1.pdf. [Last accessed 10 February 2010]
15. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186
16. Heikkinen T, Ruuskanen O. Effectiveness of influenza vaccine to prevent acute otitis media. JAMA 2004;291:692-693
17. Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003;22:S207-10
18. Gasparini R, Durando P, Ansaldi F, et al. Influenza and respiratory syncytial virus in infants and children: relationship with attendance at a paediatric emergency unit and characteristics of the circulating strains. Eur J Clin Microbiol Infect Dis 2007;26:619-628
19. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of infuenza in young children. N Engl J Med 2006;355:31-40
20. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003;21:1769-1775
21. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138
22. Vu T, Farish S, Jenkins M, et al. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-1836
23. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009;27:5043-5053
24. Lazuardi L, Jenewein B, Wolf AM, et al. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005;114:37-43
25. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2:197-203
26. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002;168:5893-5899
27. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006;333:912-915
28. Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008;15:253-259
29. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003;21:3629-3637
30. Paschke R, Pollok M, Geiger H, et al. Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in renal transplant recipients, J Prev Med Hyg 2003;44:79-84
31. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996;22:295-302
32. European Centre for Disease Prevention and Control (ECDC). Technical report on the scientific panel on vaccines and immunization. Infant and children seasonal immunization against infuenza on a routine basis during inter-pandemic period. Stockholm, 2007. Available from: http://www.ecdc.europa.eu/documents/ pdf/Flu-vacc-18-Jan.pdf. [Last accessed 10 February 2010]
33. T. Jefferson, A. Rivetti, A. Harnden, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879
34. Treanor JJ. Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med 2004;350:218-220
35. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007;25:6852-6862
36. Ansaldi F, Icardi G, Gasparini R, et al. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season. J Clin Microbiol 2005;43:3027-3029
37. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and hemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008;26:1525-1529
38. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viralmetamorphosis: the importance of cross-protection. Vaccine 2009;27:3345-3348
39. De Jong JC, Beyer WE, Palache AM, et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000;61:94-99
40. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006;24:6605-6611
41. Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007;25:2842-2851
42. Centers for Disease Control and Prevention (CDC). Influenza. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editors. Epidemiology and prevention of vaccine-preventable diseases. 10th edition. Public Health Foundation, Washington, DC; 2007b. p. 235-256
43. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26:4-29
44. Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008;118:3273-3275
45. Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004;39:920-927
46. Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650-658
47. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006;166:1121-1127
48. de B, Zanasi A, Ragusa S, et al. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin Ther 2002;24:100-111
49. Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-7312
50. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004;350:896-903
51. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-696
52. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006;355:2513-2522
53. Beran J, Ambrozaitis A, Laiskonis A, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009;7:13
54. Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Available from: http://www.emea. europa.eu/humandocs/PDFs/EPAR/intanza/H-957-en6.pdf. [Last accessed 10 February 2010]
55. Bruzzone B, Crovari P, Durando P, et al. Influenza vaccination: advantages of new generation carriers. Ann Ig 2002;14:11-18
56. Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009;27:4381-4387
57. Conne P, Gauthey L, Vernet P, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997;15:1675-1679
58. Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344:160-163
59. Ruf BR, Colberg K, Frick M, et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004;32:191-198
60. Baldo V, Menegon T, Bonello C, et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001;19:3472-3475
61. Pregliasco F, Mensi C, Serpilli W, et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 2001;13:38-43
62. de Bruijn IA, Meyer I, Gerez L, et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007;26:119-127
63. de Bruijn IA, Nauta J, Cramer WC, et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005;23:S39-49
64. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine 2005;23:S26-38
65. Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-306
66. Baldo V, Baldovin T, Floreani A, et al. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007;25:3955-3961
67. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-2680
68. Gasparini R, Pozzi T, Montomoli E, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001;17:135-140
69. Squarcione S, Sgricia S, Biasio LR, et al. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003;21:1268-1274
70. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhanced the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-184
71. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-571
72. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-6295
73. Baldo V, Baldovin T, Floreani A, et al. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007;27:542-547
74. Del Giudice G, Hilbert AK, Bugarini R, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063-3065
75. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenzaA/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943
76. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-2435
77. Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03(A) adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009;27:7428-7435
78. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28(7):1740-1745
79. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010;28:849-857
80. Leroux-Roels I, Clement F, Leroux-Roels G, et al. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly. Poster presented at Influenza Vaccines for the World; 18 - 20 October 2006a; Vienna, Austria
81. Leroux-Roels I, Oostvogels L, Hons E, et al. Reactogenicity and safety of adjuvanted influenza vaccines administered in elderly. Poster presented at Influenza Vaccines for the World; 18 - 20 October 2006b; Vienna, Austria
82. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710
83. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 2007;82:740-744
84. Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008;105:10501-10506
85. Seubert A, Monaci E, Pizza M, et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008;180:5402-5412
86. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008;26:3209-3222
87. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virusvaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized forthree consecutive influenza seasons. Vaccine 1999;17:99-104
88. Ansaldi F, Bacilieri S, Banfi F, et al. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol 2006;13:162-4
89. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, et al. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 2004;23:283-289
90. Puig-Barberà J, Díez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007;25:7313-7321
91. Iob A, Brianti G, Zamparo E, et al. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvanted vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005;133:687-693
92. Italian Ministry of Health. Announcement n.27, 4 February 2010. Influenza A/H1N1: il punto della situazione alla settimana 4 (25-31 gennaio 2010). Available from: http://www.nuovainfluenza.salute.gov.it/nuovainfluenza/ nuovaInfluenza.jsp. [Last accessed 10 February 2010]
93. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp Mol Pathol 2000;68:55-64
94. Del Giudice G, Fragapane E, Bugarini R, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol. 2006;13:1010-1013
95. Carlson BC, Jansson AM, Larsson A, et al. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000;156:2057-2065
96. Holm BC, Svelander L, Bucht A, et al. The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes. Clin Exp Immunol 2002;127:430-435
97. Satoh M, Kuroda Y, Yoshida H, et al. Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003;21:1-9
98. Novartis. Vaccine and diagnostics. Data on file; 2007
99. Frey S, Poland G, Percell S, et al. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003;21:4234-4237
100. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-6965
101. Barberà JP. MF59-adjuvanted seasonal influenza vaccine. Aging health 2009;5:475-481
102. Keren G, Segev S, Morag A, et al. Failure of influenza vaccination in the aged. J Med Virol 1988;25:85-89
103. Phair J, Kauffman CA, Bjornson A, et al. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med 1978;92:822-828
104. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986;4:38-44
105. European Medicines Agency (EMA). Focetria, pandemic influenza vaccine (surface antigen, inactivated, adjuvanted) A/California/7/2009 (H1N1). Available from: http://www.emea.europa.eu/influenza/vaccines/focetria/focetria-pi. html. [Last accessed 10 February 2010]